Robert A. Lafyatis, MD

Adjunct Professor, Medicine

Robert Lafyatis
617.638.4310
75 E. Newton St Evans Building

Biography

Dr. Lafyatis carries out patient oriented research into the cause and treatment of systemic sclerosis. This includes early phase clinical trials into new therapeutic agents in patients with systemic sclerosis. He has been investigating the mechanisms of actions and markers of response for novel therapeutics, such as the B cell depleting agent, rituximab and the immunosuppressant agent, mycophenlate. Additional studies are aimed at identifying biomarkers in systemic sclerosis using microarray gene expression analysis of skin and blood in scleroderma patients. Ongoing biomarker studies include investigation into molecular markers of pulmonary hypertension in systemic sclerosis. Dr. Lafyatis also carries out basic research into the cause of fibrosis and vasculopathy in systemic sclerosis using patient samples and murine disease models. His studies have provided key insights into one widely used model of systemic sclerosis, the tight skin mouse. His studies are currently focused on understanding how autoimmunity and the innate immune system lead to fibrosis and vascular damage. This has recently led to the discovery of increased interferon-regulated gene expression in white blood cells of patients with systemic sclerosis. Ongoing research is aimed at better understanding the cause of altered gene expression by monocytes and other cells in the innate immune system.

Other Positions

  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University

Education

  • University of Cincinnati, MD
  • Massachusetts Institute of Technology, BS

Publications

  • Published on 5/1/2020

    Maehara T, Kaneko N, Perugino CA, Mattoo H, Kers J, Allard-Chamard H, Mahajan VS, Liu H, Murphy SJ, Ghebremichael M, Fox D, Payne AS, Lafyatis R, Stone JH, Khanna D, Pillai S. Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest. 2020 May 01; 130(5):2451-2464. PMID: 31990684.

    Read at: PubMed
  • Published on 4/26/2020

    Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, Furst DE, Gordon J, Mayes M, Simms R, Lafyatis R, Martyanov V, Wood T, Whitfield ML, Constantine S, Lee E, Dgetluck N, White B. Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol. 2020 Apr 26. PMID: 32336038.

    Read at: PubMed
  • Published on 2/28/2020

    Saygin D, Tabib T, Bittar HET, Valenzi E, Sembrat J, Chan SY, Rojas M, Lafyatis R. Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension. Pulm Circ. 2020 Jan-Mar; 10(1). PMID: 32166015.

    Read at: PubMed
  • Published on 2/17/2020

    Lear TB, Lockwood KC, Larsen M, Tuncer F, Kennerdell JR, Morse C, Valenzi E, Tabib T, Jurczak MJ, Kass DJ, Evankovich JW, Finkel T, Lafyatis R, Liu Y, Chen BB. Kelch-like protein 42 is a profibrotic ubiquitin E3 ligase involved in systemic sclerosis. J Biol Chem. 2020 Mar 27; 295(13):4171-4180. PMID: 32071084.

    Read at: PubMed
  • Published on 1/30/2020

    Mallampalli RK, Li X, Jang JH, Kaminski T, Hoji A, Coon T, Chandra D, Welty S, Teng Y, Sembrat J, Rojas M, Zhao Y, Lafyatis R, Zou C, Sciurba F, Sundd P, Lan L, Nyunoya T. Cigarette smoke exposure enhances transforming acidic coiled-coil-containing protein 2 turnover and thereby promotes emphysema. JCI Insight. 2020 Jan 30; 5(2). PMID: 31996486.

    Read at: PubMed
  • Published on 1/7/2020

    Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity. 2020 01 14; 52(1):183-199.e9. PMID: 31924475.

    Read at: PubMed
  • Published on 12/10/2019

    Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox DA, Furst DE. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2020 01; 72(1):125-136. PMID: 31342624.

    Read at: PubMed
  • Published on 11/29/2019

    Xue D, Tabib T, Morse C, Lafyatis R. Transcriptome landscape of myeloid cells in human skin reveals diversity, rare populations and putative DC progenitors. J Dermatol Sci. 2020 Jan; 97(1):41-49. PMID: 31836271.

    Read at: PubMed
  • Published on 11/11/2019

    Distler JHW, Györfi AH, Ramanujam M, Whitfield ML, Königshoff M, Lafyatis R. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol. 2019 12; 15(12):705-730. PMID: 31712723.

    Read at: PubMed
  • Published on 10/3/2019

    Lear TB, McKelvey AC, Evankovich JW, Rajbhandari S, Coon TA, Dunn SR, Londino JD, McVerry BJ, Zhang Y, Valenzi E, Burton CL, Gordon R, Gingras S, Lockwood KC, Jurczak MJ, Lafyatis R, Shlomchik MJ, Liu Y, Chen BB. KIAA0317 regulates pulmonary inflammation through SOCS2 degradation. JCI Insight. 2019 Oct 03; 4(19). PMID: 31578312.

    Read at: PubMed

View 178 more publications: View full profile at BUMC

View all profiles